AR029642A1 - Una molecula de adn aislada que codifica un ligando denominado fhm que pertenece a la familia de supergenes de ligandos de tnf, polipeptidos de fhm, anticuerpos que conjugan fhm, materiales que integran dicha molecula y metodos de uso de dichas moleculas, metodos y compuestos farmaceuticos, metodos - Google Patents

Una molecula de adn aislada que codifica un ligando denominado fhm que pertenece a la familia de supergenes de ligandos de tnf, polipeptidos de fhm, anticuerpos que conjugan fhm, materiales que integran dicha molecula y metodos de uso de dichas moleculas, metodos y compuestos farmaceuticos, metodos

Info

Publication number
AR029642A1
AR029642A1 ARP000104020A ARP000104020A AR029642A1 AR 029642 A1 AR029642 A1 AR 029642A1 AR P000104020 A ARP000104020 A AR P000104020A AR P000104020 A ARP000104020 A AR P000104020A AR 029642 A1 AR029642 A1 AR 029642A1
Authority
AR
Argentina
Prior art keywords
fhm
methods
metolosmosuas
supergenes
polypeptides
Prior art date
Application number
ARP000104020A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR029642A1 publication Critical patent/AR029642A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un nuevo ligando de receptor, designado Fhm, que pertenece a la familia de los supergenes de los ligandos de TNF y las moléculas de ácido nucleico que los codifica. También se ocupa de vectores, células huéspedes, anticuerpos anti-Fhm y métodos recombinantes para la produccion de polipéptidos Fhm. También proporciona el uso del polipéptido Fhm recombinante para identificar parejas/receptores aglutinantes putativas. Adicionalmente, el invento provee métodos y reactivos para el diagnostico de enfermedades asociadas con Fhm anormal o la expresion anormal de su receptor putativo; y métodos y compuestos farmacéuticos para el tratamiento de enfermedades asociadas con Fhm anormal o la expresion anormal de Fhm y/o su receptor. Así mismo divulga compuestos farmacéuticos para el uso en el tratamiento de estas enfermedades.
ARP000104020A 1999-08-04 2000-08-04 Una molecula de adn aislada que codifica un ligando denominado fhm que pertenece a la familia de supergenes de ligandos de tnf, polipeptidos de fhm, anticuerpos que conjugan fhm, materiales que integran dicha molecula y metodos de uso de dichas moleculas, metodos y compuestos farmaceuticos, metodos AR029642A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14729499P 1999-08-04 1999-08-04

Publications (1)

Publication Number Publication Date
AR029642A1 true AR029642A1 (es) 2003-07-10

Family

ID=22521006

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104020A AR029642A1 (es) 1999-08-04 2000-08-04 Una molecula de adn aislada que codifica un ligando denominado fhm que pertenece a la familia de supergenes de ligandos de tnf, polipeptidos de fhm, anticuerpos que conjugan fhm, materiales que integran dicha molecula y metodos de uso de dichas moleculas, metodos y compuestos farmaceuticos, metodos

Country Status (9)

Country Link
US (4) US6521422B1 (es)
EP (1) EP1210435A1 (es)
JP (1) JP2003506088A (es)
AR (1) AR029642A1 (es)
AU (1) AU783682B2 (es)
CA (1) CA2381284A1 (es)
MX (1) MXPA02001264A (es)
TW (1) TW200716746A (es)
WO (1) WO2001011050A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599719B2 (en) * 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US20030203435A1 (en) * 1998-04-30 2003-10-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
JP2003506088A (ja) * 1999-08-04 2003-02-18 アムジェン インコーポレーテッド ＴＮＦリガンドスーパー遺伝子ファミリーの新規のメンバーであるＦｈｍ
AU2003253381A1 (en) * 2002-08-06 2004-02-25 Aplagen Gmbh Binding molecules
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP2005173484A (ja) * 2003-12-15 2005-06-30 Canon Inc 画像形成装置及びプロセスカートリッジ
EP2412816B1 (en) 2004-07-26 2014-12-03 Pfenex Inc. Process for improved protein expression by strain engineering
US7292198B2 (en) * 2004-08-18 2007-11-06 Ruckus Wireless, Inc. System and method for an omnidirectional planar antenna apparatus with selectable elements
US7193562B2 (en) 2004-11-22 2007-03-20 Ruckus Wireless, Inc. Circuit board having a peripheral antenna apparatus with selectable antenna elements
US7358912B1 (en) 2005-06-24 2008-04-15 Ruckus Wireless, Inc. Coverage antenna apparatus with selectable horizontal and vertical polarization elements
US7893882B2 (en) 2007-01-08 2011-02-22 Ruckus Wireless, Inc. Pattern shaping of RF emission patterns
MX2009011523A (es) 2007-04-27 2009-11-09 Dow Global Technologies Inc Metodo para clasificar rapidamente huespedes microbianos para identificar ciertas cepas con rendimiento y/o calidad mejorados en la expresion de proteinas heterologas.
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US8217843B2 (en) 2009-03-13 2012-07-10 Ruckus Wireless, Inc. Adjustment of radiation patterns utilizing a position sensor
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
US8756668B2 (en) 2012-02-09 2014-06-17 Ruckus Wireless, Inc. Dynamic PSK for hotspots
US10186750B2 (en) 2012-02-14 2019-01-22 Arris Enterprises Llc Radio frequency antenna array with spacing element
US9634403B2 (en) 2012-02-14 2017-04-25 Ruckus Wireless, Inc. Radio frequency emission pattern shaping
US9092610B2 (en) 2012-04-04 2015-07-28 Ruckus Wireless, Inc. Key assignment for a brand
KR102366076B1 (ko) 2013-11-13 2022-02-21 화이자 인코포레이티드 종양 괴사 인자-유사 리간드 1a 특이적 항체 및 그의 조성물 및 용도
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107267A (en) 1993-10-12 2009-07-20 Yeda Res & Dev Ligand to a member of the tnf/ngf receptor family
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US6541610B1 (en) 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
NZ237669A (en) 1990-04-13 1992-08-26 Res Dev Foundation T-cell proteins expressed in t-cell development and their preparation
NZ251820A (en) 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
AU670125B2 (en) 1992-09-15 1996-07-04 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US20030198640A1 (en) 1994-11-07 2003-10-23 Human Genome Sciences, Inc. Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta
US20030129189A1 (en) 1994-11-07 2003-07-10 Guo-Liang Yu Tumor necrosis factor-gamma
US6824767B2 (en) * 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
KR100507431B1 (ko) 1994-11-07 2005-12-21 휴먼 게놈 사이언시즈, 인코포레이티드 종양괴사인자-γ
US6599719B2 (en) 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5843789A (en) 1995-05-16 1998-12-01 Neomecs Incorporated Method of analysis of genomic biopolymer and porous materials for genomic analyses
RU97121687A (ru) 1995-05-26 2005-01-20 Синджента Лимитед (Gb) Ген-переключатель, представляющий ген рецептора экдизона
US20040013664A1 (en) 1997-01-14 2004-01-22 Gentz Reiner L. Tumor necrosis factor receptors 6 alpha & 6 beta
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
US8003386B1 (en) 1997-01-14 2011-08-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α and 6β
US5863769A (en) 1997-01-28 1999-01-26 Smithkline Beecham Corporation DNA encoding interleukin-1 receptor antagonist (IL-1raβ)
US5885800A (en) * 1997-02-04 1999-03-23 Smithkline Beecham Corporation DNA encoding tumor necrosis related receptor, TR4
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
TW562807B (en) 1997-04-01 2003-11-21 Chugai Pharmaceutical Co Ltd Novel secretory membrane protein
AU8395798A (en) 1997-07-15 1999-02-10 Immunex Corporation Trail receptor
WO1999004001A1 (en) 1997-07-21 1999-01-28 Zymogenetics, Inc. Tumor necrosis factor receptor ztnfr-5
AU751396B2 (en) 1997-08-04 2002-08-15 Millennium Pharmaceuticals, Inc. Novel molecules of the Tango-77 related protein family and uses thereof
CA2299619A1 (en) 1997-08-06 1999-02-18 Regeneron Pharmaceuticals, Inc. Human orphan receptor ntr-1
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
IL134578A0 (en) 1997-09-18 2001-04-30 Genentech Inc DcR3 POLYPEPTIDE, A TNFR HOMOLOG
WO1999020758A1 (en) 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
US20020111325A1 (en) 1997-11-03 2002-08-15 Human Genome Sciences, Inc. VEGI, an inhibitor of angiogenesis and tumor growth
CA2309541C (en) * 1997-11-03 2011-01-11 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
WO1999026977A1 (en) 1997-11-24 1999-06-03 Biogen, Inc. Novel receptors opg-2
EP1037908A2 (en) 1997-12-16 2000-09-27 Incyte Pharmaceuticals, Inc. Human tumor necrosis factor-r2-like proteins
NZ505881A (en) 1998-01-09 2003-05-30 Immunex Corp IL-1 delta DNA and polypeptides
DE19809978A1 (de) 1998-03-09 1999-09-16 Basf Ag Neuer Rezeptor aus der menschlichen Lunge
IL138626A0 (en) 1998-03-30 2001-10-31 Lilly Co Eli Therapeutic applications of mature flint (mflint) polypeptides or opg3, a member of the receptor superfamily
CA2326066A1 (en) 1998-04-03 1999-10-14 Hyseq, Inc. A interleukin-1 receptor antagonist and uses thereof
US6274339B1 (en) * 1999-02-05 2001-08-14 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of body weight disorders, including obesity
AU6280999A (en) 1998-09-30 2000-04-17 Millennium Pharmaceuticals, Inc. Novel secreted immunomodulatory proteins and uses thereof
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
US20030096355A1 (en) 1999-07-09 2003-05-22 Ke Zhang Isolation, identification and characterization of ymkz5, a novel member of the TNF-receptor supergene family
JP2003506088A (ja) * 1999-08-04 2003-02-18 アムジェン インコーポレーテッド ＴＮＦリガンドスーパー遺伝子ファミリーの新規のメンバーであるＦｈｍ
US6569685B1 (en) * 1999-10-05 2003-05-27 The Molecular Sciences Institute, Inc. Protein fingerprint system and related methods

Also Published As

Publication number Publication date
US20030129706A1 (en) 2003-07-10
US20040265913A1 (en) 2004-12-30
CA2381284A1 (en) 2001-02-15
US6852839B2 (en) 2005-02-08
TW200716746A (en) 2007-05-01
MXPA02001264A (es) 2002-07-22
US7544519B2 (en) 2009-06-09
US6521422B1 (en) 2003-02-18
EP1210435A1 (en) 2002-06-05
AU2807101A (en) 2001-03-05
US20040248324A1 (en) 2004-12-09
AU783682B2 (en) 2005-11-24
JP2003506088A (ja) 2003-02-18
WO2001011050A1 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
AR029642A1 (es) Una molecula de adn aislada que codifica un ligando denominado fhm que pertenece a la familia de supergenes de ligandos de tnf, polipeptidos de fhm, anticuerpos que conjugan fhm, materiales que integran dicha molecula y metodos de uso de dichas moleculas, metodos y compuestos farmaceuticos, metodos
BR9713727A (pt) Corpos oleosos e proteìnas associados como matrizes de afinicade.
LINKE et al. β 2-microglobulin, different fragments and polymers thereof in synovial amyloid in long-term hemodialysis
CO2021011327A2 (es) Anticuerpos y receptores quiméricos de antígenos específicos para receptor 1 huérfano tipo receptor tirosina-cinasa (ror1)
AR079274A1 (es) Proteinas de enlace a antigenos (humanas) que enlazan (beta)-klotho, receptores fgf y complejo de los mismos
Domenicucci et al. Characterization of porcine osteonectin extracted from foetal calvariae
AR062867A2 (es) Proteinas de enlace a interleuquina -18, (il- 18bp), secuencias de adn que codifican para la il -18 bp, secuencias de adnc, un vehiculo de expresion replicable, celula huesped, un proceso para su produccion y aislacion, anticuerpos, composiciones farmaceuticas, el uso de dichas composiciones para la
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
DK0914345T3 (da) Antistoffer, som binder til monocyt-kemoattraktant-protein-1-receptor (MCP-1-receptor) (CCR2)
ATE403001T1 (de) Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
AR020048A1 (es) Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.
EA200701211A1 (ru) Полипептиды, которые связываются с br3, и их применение
ATE377081T1 (de) Material und verfahren die hybridvaskularendothelwachstumfaktoren dns und proteine enthalten und screeningverfahren für modulatoren
ATE370967T1 (de) Polyspezifische bindemoleküle und deren verwendung
ATE391778T1 (de) Mutanten des vaskulären, endothelzellen- spezifischen wachstumsfaktors c (vegf-c) und deren verwendungen
CL2010001209A1 (es) Anticuerpos monoclonales aislados que preferentemente se unen al polipeptido ca 125/o772p asociado a celulas en relacion al polipeptido ca 125/o772p soluble; hibridoma; acido nucleico que los codifica; composicion farmaceutica; kit polipeptido de fusion; y su uso para preparar un medicamento para tratar un desorden celular proliferativo (divisional de sol. n° 2086-03).
AR061107A1 (es) Anticuerpos bloqueantes de la funcion de la integrina (alfa)5(beta)1 humanos y humanizados de gran afinidad con inmunogenicidad reducida
NO963371L (no) Hematopoietisk protein samt materialer og fremgangsmåter for fremstilling av det
DK1666052T3 (da) Anti-APRIL monoklonalt antistof og dets anvendelse til behandling af en immum-relateret sygdom eller cancer
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
ATE196314T1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
AR075047A1 (es) Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga. polipeptido purificado. anticuerpo ant-stx2. kit.
ES2085993T3 (es) Proteina asociada a la pancreatitis aguda, medios para el diagnostico de la pancreatitis aguda.
GEP20094629B (en) Nogo receptor binding protein
DE69636437D1 (de) Ligand polypeptide für hypophyse g-protein gekoppeltes rezeptor-protein, deren herstellung und anwendung

Legal Events

Date Code Title Description
FB Suspension of granting procedure